Gamma scintigraphy is a non-invasive technique with applications in the development of drug products and the assessment of pharmacodynamic effects in humans. It enables the assessment of critical performance parameters that in vitro techniques attempt, but often fail, to predict. Quantification of pharmacodynamic effects (eg gastrointestinal transit; gall bladder emptying; lung mucociliary clearance) provides insights into the mode of action of drug candidates.
The cost of developing a new drug product is now estimated to exceed $1.5 billion, with an estimated $20 million being spent per molecule in the early development phase (1). Currently, ~70% of these projects will fail at, or before proof of concept (2).
This, coupled with the threat from generic competition, has resulted in a drive for reinvention of the pharmaceutical industry. A more efficient, cost-effective model is being implemented with the aim of increasing the number of drug candidates available for development, and simultaneously reducing late stage attrition (3).
This strategy hinges on the use of innovative clinical protocols in early development to enable detailed, scientifically-driven investigation of product performance. The development team needs access to a full range of tools that can be integrated into routine early development studies, enhancing the data obtained.
Gamma scintigraphy is one such tool. It provides the means to assess critical-to-performance parameters, which in vitro methods attempt but often fail to predict. It also provides a gold standard method for the direct quantification of pharmacodynamic effects, providing insight into mode of action of drug candidates.
Gamma scintigraphy is an imaging technique that enables the direct visualisation and quantification of events occurring in vivo, in real time. Initially introduced as diagnostic tool, the potential of this method was quickly realised within the pharmaceutical industry. Gamma scintigraphy was first reported for the measurement of transit times in 1966 (gastric emptying) followed swiftly by the assessment of drug product performance in 1976 (capsule disintegration) (4,5).
Visualisation is achieved by the incorporation of short half-life gamma emitting radionuclides, eg technetium-99m (99mTc) and indium-111 (111In). The chosen radionuclide(s) is used to label the drug product or, for pharmacodynamic investigations, the component of interest (eg food or fluid for gastrointestinal transit; inhaled particles for mucociliary clearance). The radiation dose to the subject is minimal – often not exceeding that received from a single X-ray. A gamma camera is used to detect the gamma rays and record these as primary counts which are represented as an image (Figure 1).
Gamma scintigraphic investigations can be routinely incorporated into standard phase 1/2a studies alongside safety, pharmacokinetic and other biomarker assessments.
Applications in drug product development
The production of an oral product starts in the laboratory, where the pharmaceutical scientist is charged with developing a dosage form which meets a pre-determined specification for drug release. Release rate is measured by recognised methods, for example dissolution testing coupled with HPLC, to generate a profile of drug release versus time. The primary use of these data is for the comparison/differentiation of prototype formulations, and for quality control.
However, the results are also often intended as a representation of formulation performance in simulated in vivo conditions and are used as a first stage tool for formulation selection. However, an in vitro method cannot take into account all of the physiological factors that influence formulation performance and even if an in vitro-in vivo correlation (IVIVC) can be established, this is only confirmed after completion of a clinical study.
Clinical studies designed to assess the performance of prototype formulations generate pharmacokinetic parameters. These data are at least onestep removed from formulation performance and so, when the pharmacokinetic profile is not as predicted, educated guesswork is needed to determine – and more importantly, fix – the cause.
Scintigraphic data provide the missing information, offering real-time visualisation and measurement of in vivo formulation performance. Key data are the rate of erosion of the dosage form – equating to release of drug (Case study 1) (6).
These data correspond to those obtained from in vitro dissolution, and assuming no other rate limiting factors may also parallel the appearance of drug in the systemic circulation (Figure 2).
A further level of detail is obtained by tracking the transit of the dosage form through the gastrointestinal tract. How long does a gastroretentive formulation remain in the stomach? To which regions does an extended release formulation deliver? How rapidly does an enteric coated formulation deliver drug after gastric emptying? Does a colon targeting formulation reproducibly deliver to the target site? (7-11).
Oral inhaled products
The success of an orally inhaled product is a combination of the device, the formulation and the patient’s technique (12). As with oral formulations, development starts in the laboratory and the performance of prototypes is measured via particle size distribution (PSD) testing. While attempts continue to use PSD profiles as a predictor of in vivo deposition, the reality is that there is no direct correlation between individual or grouped stages and the anatomy of the lungs (13).
Consequently, while comparable in vitro performance can be used to support claims of equivalence, de novo data cannot be relied upon to predict lung deposition. Products for oral inhalation can be radiolabelled by the addition of a radionuclide (eg 99mTc) to the formulation.
In vitro testing is performed to confirm that the PSD of the radiolabel and the drug matches, ensuring that the deposition pattern of the radiolabel is representative of the drug molecule (14). Scintigraphic data are most commonly used to quantify the initial deposition pattern providing a measure of how efficiently the device delivers the formulation, to which anatomical regions and the extent of lung penetration.
Nasal administration is used for delivery to the systemic circulation (large surface area, non-invasive delivery) or for local delivery (15). Delivery via the nasal cavity has been explored to deliver drug to the sinuses, and also to the olfactory region to achieve delivery to the brain. Consequently, drug products are often designed to target delivery to specific regions of the nasal cavity.
Scintigraphic images co-registered with an MRI scan of the head can be used to quantify the amount of drug formulation delivered to target sites. Specific anatomical regions can be identified, or the cavity can be divided into zones such as upper:lower:inner:outer (16). Further, scintigraphic imaging can provide evidence to support statements to the regulators that nasal delivery results in no deposition to the lungs.
Locally acting drug molecules
The quantification of the availability of the active moiety at the site of action, ie the measurement of bioavailability, is a fundamental element of pharmaceutical development. For molecules which reach their site of action via the systemic circulation, pharmacokinetic parameters are an accepted surrogate measure and these data underpin the majority of safety, efficacy and bioequivalence assessments. However, for molecules that do not rely on systemic availability, this raft of assessments can be challenging to complete.
Bioavailability may be assessed by ‘measurements intended to reflect the rate and extent to which the API becomes available at the site of action’ (17,18). Traditionally, for locally acting drugs these measurements have been limited to pharmacodynamic assessments, and large clinical trials to confirm efficacy. For locally acting molecules delivered via the oral inhaled route, the use of in vitro assessments and the quantification of lung deposition via imaging are already recognised as supporting data – although pharmacokinetic data are still deemed to be advantageous (19,20).
The regulators now also recognise that the use of comparative clinical trials is inefficient and prohibitively expensive for locally acting molecules delivered to the gastrointestinal tract. As part of the FDA Critical Path Initiative, in vivo imaging has been suggested as a method to directly assess the rate of drug release at the target site (21). Scintigraphic data provides a measure of both the location and rate of drug release, and comparative assessments of innovator versus test product can be performed.
Applications in clinical pharmacology
Drug molecules often have an impact on gastrointestinal transit. This may be an unwanted side effect, such as opioid-induced constipation, or a key element of the molecule’s pharmacology, eg 5- HT4 agonists (22,23). This impact can be measured in a variety of ways – from changes in acetaminophen kinetics, to the 13C octanoic acid or hydrogen breath tests, the use of radio-opaque markers and the measurement of pH changes (24-27). However, each of these approaches provides limited insight into the extent of the effect exerted by the drug molecule.
Scintigraphic imaging is a convenient method providing direct, detailed, quantitative assessment of gastrointestinal transit. The radiolabel is administered in food and/or fluid, or as a multi-particulate formulation, which provides a marker for gastrointestinal contents without concomitant administration of calories and induction of the fed state. The method permits a detailed assessment of the effect of a drug molecule on gastric emptying (28).
Solid and liquid phase gastric emptying, which are regulated by different mechanisms and hence can be affected differentially, can be measured concurrently by the simultaneous use of two radionuclides. Detailed analysis of intra-gastric distribution can also be performed.
Similarly, the impact of a drug molecule on colon transit can be a desired pharmacological effect, ie the normalisation of transit times to treat diarrhoea or constipation, or it can be an adverse effect resulting in the generation of these symptoms. The rate of colon transit is measured by a technique termed geometric centre (GC) analysis. The method was first presented in 1986, and has developed since then to offer a non-invasive measure of transit through the colon versus time (29,30) (Figure 3). The data generated are both stable and clinically relevant (31).
A healthy volunteer model for the assessment of the sub-clinical effect of drug molecules on colon transit is available (Case study 2). Effects on colon transit are observed, following single doses, prior to the onset of any signs or symptoms of disruption of the normal pattern of motility (32-34). This provides the opportunity to assess the effect of new drug products in simple, efficient investigations that can be performed early in the development process.
Mucociliary clearance is the primary physiologic defence mechanism, protecting the lungs from damage caused by inhaled particles and microorganisms. Impairment of mucociliary clearance function plus airway inflammation in conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) may contribute to the increased morbidity from airway infections that are part of these conditions. Consequently, the quantification of the impact of drug molecules on the rate of mucociliary clearance is a key biomarker for products in development for the treatment of respiratory disease (35).
Scintigraphic assessment of mucociliary clearances enabled by administration to the lungs of radiolabelled non-absorbable particles, including 99mTc labelled sulphur colloid (36,37). Following deposition, the rate of removal of these particles is primarily governed by mucociliary clearance. Sequential scintigraphic images are acquired and the rate of clearance quantified. Results for the test regimen can be compared with baseline, placebo or positive control (eg hypertonic saline) (38). Dose ranging assessments can also be performed (39).
The utilisation of gamma scintigraphic techniques within the pharmaceutical industry is continually progressing, and the latest transition from diagnosis (hepatobiliary disease) into clinical research is the impact of drug molecules on the rate of gallbladder emptying. The drive for this transition was the concern voiced by the FDA of the potential for GLP-1 analogues and agonists to induce acute pancreatitis following post-marketing reports for exenatide (40). This led to the requirement for the assessment of gallbladder emptying for new molecules within this class.
A number of variations of the method are routinely used within a diagnostic setting (41,42). In order to ensure consistent and comparable data, the method was adapted and standardised. Recommended parameters have been published (Figure 4) (43).
Gamma scintigraphy is an in vivo imaging tool with many applications within the pharmaceutical industry. It is recognised as the gold standard technique and is routinely used as the benchmark, which alternative methods have to meet. For drug product development, it is the only direct method of assessment of critical-to-performance parameters which in vitro methods attempt but often fail to predict.
It also permits direct quantification of pharmacodynamic effects, providing insight into mode of action of drug candidates and essential biomarker data. The data generated are accurate, detailed, comprehensive and clinically relevant, resulting in greater confidence in decision making leading to more effective drug product development.
Scintigraphic imaging is a tool that every pharmaceutical scientist and clinical pharmacologist should have access to in order to improve early development productivity.
Dr Alyson Connor gained her PhD in 1998 and has 15 years’ experience in the pharmaceutical industry. For the past 12 years Alyson has fulfilled the role of Senior Research Fellow at Quotient Clinical, a provider of early drug development services. As lead scientist she is responsible for all oral scintigraphic studies performed and is an acknowledged expert in the use of scintigraphy to assess product performance and pharmacodynamic effect. She regularly publishes on this subject.
1 Evaluate Pharma Alpha World preview 2014. Evaluate Pharma report, 2009.
2 Kola, I, Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Disc 2004. 3:711-715.
3 Paul, SM, Mytelka, DS, Dunwiddie, CT, Persinge, CC, Munos, BH, Lindborg, SR. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Rev Drug Disc 2010. 9:203-214.
4 Griffith, GH, Owen, GM, Kirkman, S, Shields, R. Measurement of rate of gastric emptying using chromium-51. Lancet 1966. 1:1244-1245.
5 Casey, DL, Beihn, RM, Digenis, OA, Shambhu, MB. Method for monitoring hard gelatin capsule disintegration times in humans using external scintigraphy. J Pharm Sci 1976. 65:1412-1413.
6 Davis, J, Burton, J, Connor, AL, MacRae, R, Wilding, IR. Scintigraphic study to investigate the effect of food on a HPMC modified release formulation of UK-294,315. J Pharm Sci 2009. 98:1568-1576.
7 Hou, SYE, Cowles, VE, Berner, BE. Gastric retentive dosage forms: A review. Crit Rev ther Drug carrSyst 2003. 20:461-497.
8 Lobo, ED et al. Optimization of LY545694 tosylate controlled release tablets through pharmacoscintigraphy. Pharm Res 2012. In press.
9 Cole, ET, Scott, RA, Connor, AL et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. International Journal of Pharmaceutics 2002. 231:83-95.
10 Sinha, A, Ball, DJ, Connor, AL, Nightingale, J, Wilding, IR. Intestinal performance of two mesalamine formulations in patients with active ulcerative colitis as assessed by gamma scintigraphy. Pract Gastro 2003. XXVII.56–69.
11 Hilton, JE. Delivering drugs to the colon using COLAL®: a modified-release delivery system. Eur J Parent Pharm Sci 2008. 13:43-49.
12 Newman, SP. Optimizing delivery of drugs to the lungs. Clin Asthma rev 1998. 2:123-128.
13 Newman, SP, Wilding, IR, Hirst, PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 2000. 208:49-60.
14 Snell, NJ, Ganderton, D. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998.Respir Med 1999. 93:123-133.
15 Newman, SP, Pitcairn, GR, Dalby, RN. Drug delivery to the nasal cavity: in vitro and in vivo assessment. Crit Rev Ther Drug Carr Syst 2004. 21:21-66.
16 Suman, JD, Laube, BL, Dalby, R. Nasal nebulisers versus aqueous nasal spray pumps: a comparison of deposition patterns in human volunteers. Resp Drug Del VI 1998. 211-218.
17 Note for Guidance on the investigation of bioavailability and bioequivalence. Committee for Proprietary Medicinal Products (CPMP), The European Agency for the Evaluation of Medicinal Products (EMEA). London, 26 July 2001.
18 Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products – general considerations. US Dept of Health and Human Services, FDA. Centre for Drug Evaluation and Research (CDER). March 2003.
19 Guideline on the requirement for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Committee on Medicinal Products for Human Use (CHMP), The European Medicines Agency (EMA). London, 18 October 2007.
20 O’Connor, D, Adams, WP, Chen, ML. Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: Workshop summary report. J Aer Med Pul Drug Del 2011. 24:119-135.
21 Critical path opportunities for generic drugs. Office of Generic Drugs. Office of Pharmaceutical Science. Centre for Drug Evaluation and Research (CDER). 1 May 2007.
22 Panchal, SJ, Müller-Schwefe, P, Wurzelmann, JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J ClinPract 2007. 61:1181-1187.
23 Hegde, SS, Eglen, RM. Peripheral 5-HT4 receptors. FASEB J 1996. 10:1398-1407.
24 Nimmo, J, Heading, RC, Tothill, P, Prescott, LF. Pharmacological modification of gastric emptying: effects of propantheline and metoclopramide on paracetamol absorption. Br Med J 1973. 1:587-589.
25 Ghoos, YF, Maes, BD, Geypens, BJ et al. Measurement of gastric emptying rate of solids by means of a carbon-labeledoctanoic acid breath test. Gastroenterology 1993. 104:1060- 1647.
26 Gasbarrini, A, Corazza, GR, Gasbarrini, G et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: The Rome Consensus Conference. Aliment PharmacolTher 2009. 29 (suppl 1):1-49.
27 Kuo, B, McCallum, RW, Koch, KL et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment PharmacolTher 2008. 27:186-196.
28 Linnebjerg, H, Park, S, Kothare, PA et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regulatory Peptides 2008. 151: 123- 129.
29 Krevsky, B, Malmud, LS, D’Ercole, F, Maurer, AH, Fisher, RS. Colonic transit scintigraphy. A physiologic approach to the quantitative measurement of colonic transit in humans. Gastroenterology 1986. 91:1102-1012.
30 Krevsky, B, Maurer, AH, Niewiarowski, T, Cohen, S. Effect of verapamil on human intestinal transit. Dig Dis Sci 1992. 37:919-924.
31 Cremonini, F, Mullan, BP, Camilleri, M, Burton, DD, Rank, MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment PharmacolTher. 2002. 16:1781-1790.
32 Wilding, IR, Richards, JC, Whipps, C, Monteith, D. Pharmacoscintigraphic evaluation of a new “once-a-day” morphine preparation (OSAT®). Poster presentation AAPS 1998.
33 Malhotra, BK, Damle, B, Darekar, A et al. Tolterodine extended release does not affect gastrointestinal motility in the elderly. Poster presentation EUGMS 2006.
34 Smith, K, Hopp, M, Mundin, G et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opinion Investigational Drugs 2011. 20:1-13.
35 Pavia D, Sutton, PP, Agnew, JE, Lopez-Vidriero, MT, Newman, SP, Clarke, SW. Measurement of bronchial mucociliary clearance. Eur J Respir dis 1983. 64(suppl 127):41-56.
36 Donaldson, SH, Corcoran, TE, Laube, BL, Bennett, WD. Mucociliary clearance as an outcome measure for cystic fibrosis in clinical research. Proc Am ThoracSoc 2007. 4:399-405.
37 Limb, M, Bacon, R, Scholes, P, Longphre, M. Utility of gamma scintigraphy in assessing mucociliary clearance in COPD. Poster presentation Drug Delivery to the Lungs 2007.
38 Robinson, M, Hemming, AL, Regnis, JA et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997. 52:900-903.
39 Patrick, L, Connor, A, Mair, S, Collier, J, Rosano, M, Hanrahan, J. Design and implementation of a multi-part, flexible protocol to assess the tolerability and pharmacodynamic effects of PUR118 in healthy subjects and COPD patients. Poster presentation – abstract accepted. European Respiratory Society Annual Congress 2012.
40 Correspondence between CDER, FDA and Amyllin Pharmaceuticals. Oct 2009. http://www.accessdata.fda.gov/drugsatfda_docs/a ppletter/2009/021773s009s011s017s018s022s02 5021919ltr.pdf.
41 Krishnamurthy, S, Krishnamurthy, GT. Effect of sequential administration of an opioid and cholecystokinin on gallbladder ejection fraction: brief communication. J Nucl Med 2006. 47:1463-1466.
42 Zeissman, HA, Tulchinsky, T, Lavely, WC et al. Sinaclatide-stimulated cholescintigraphy: A multicentre investigation to determine optimal infusion methodology and gallbladder ejection fraction normal values. J Nucl Med 2010. 51:277-281.
43 Connor, A, Collier, J, Rowley, K, Perkins, A. Application of a diagnostic technique for assessment of the effect of GLP-1 analogues / agonists on gallbladder emptying. Poster presentation ASCPT 2011.